SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Facade of Novo Nordisk's office in Fremont, California
Weight loss
Novo Challenges Lilly With up to $2B Bet for Triple-G Obesity Drug From Chinese Biotech
Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a mid-stage study.
March 24, 2025
 · 
2 min read
 · 
Tristan Manalac
Facade of AstraZeneca's office in Shanghai, China
China
AstraZeneca Makes Potential $10B+ China Commitment Despite Political Pressure
The investments come amid an ongoing insurance fraud probe into AstraZeneca’s former China head Leon Wang—and despite mounting pressure from President Trump for pharma companies to re-shore their manufacturing operations.
March 24, 2025
 · 
2 min read
 · 
Tristan Manalac
Paper torn and revealing dollar bill. Financial investment and cash income
Legal
AbbVie Lawsuit Alleges That Partner Genmab “Misappropriated” Trade Secrets
AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s investigational antibody-drug conjugates. Genmab acquired ProfoundBio in May 2024.
March 24, 2025
 · 
2 min read
 · 
Tristan Manalac
IN PARTNERSHIP WITH SMARTLABS
How Modern Vivarium Services Are Revolutionizing Drug Development
In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.
March 24, 2025
 · 
7 min read
 · 
BioSpace Insights
Vector illustration of pig in graphic style. Drawing by hand.
Drug Development
Gene Editing, Next-Gen Antibodies Key to Unlocking Animal-to-Human Transplants
It’s early days for xenotransplantation, but eGenesis, Eledon, United Therapeutics and more are working to develop solutions to make this approach a viable option and help ease the organ shortage crisis.
March 24, 2025
 · 
8 min read
 · 
Kate Goodwin
Bureaucracy and administration management success with a group of tangled red tape and people running away on a pencil drawing line as a bureaucratic solution symbol with 3D illustration elements.
Opinion
Biosimilars Shouldn’t Be This Hard To Bring to Market
Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of branded biologics looking to maintain blockbuster revenue.
March 24, 2025
 · 
7 min read
 · 
Sarfaraz K. Niazi
Empty Wheelchair under Cloud in Desert on a blue sky background. 3d Rendering
Spinal muscular atrophy
6 Therapies on the Horizon for Spinal Muscular Atrophy
Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several companies—including Novartis, Scholar Rock and Biogen—progressing novel candidates through clinical trials.
March 24, 2025
 · 
5 min read
 · 
Natalia Mesa
Background of scattered on a plain blue background of many tablets in the form of a silhouette of the continents of the world 3d illustration
Manufacturing
J&J Joins Pharma Peers With $55B US Manufacturing Boost Following Trump’s Tariff Threats
Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major tariffs on pharmaceutical products. Pfizer has also promised a similar commitment.
March 21, 2025
 · 
2 min read
 · 
Annalee Armstrong
Vector illustration representing kidney care, highlighting the importance of health and medical attention for these vital organs
Rare diseases
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
March 21, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS